Summary
Other Scenarios:
- VRX - PFE
- VRX - GSK
- PFE - PHRM
- GSK - PHRM
| Buyer: | Valeant Pharmaceuticals International (VRX) | Last Price: | 16.18 | Market Cap.: | 1.49B |
|---|---|---|---|---|---|
| Target: | Pharmion Corporation (PHRM) | Last Price: | 38.64 | Market Cap.: | 1.43B |
Lines of Business Summary:
- Valeant Pharmaceuticals International (VRX) competes in 1 industry and 47 product/service groups
- Pharmion Corporation (PHRM) competes in 1 industry and 6 product/service groups
- A combined entity will have 0% Product/Service Group overlap
- Valeant Pharmaceuticals International (VRX) has 0 and Pharmion Corporation (PHRM) has 1 suppliers that rely on a material % of their business. They share 0 in common.
- Valeant Pharmaceuticals International (VRX) has 1 and Pharmion Corporation (PHRM) has 3 customers that derive significant revenue from each. They share 1 in common.
Product Summary:
Overlap & Complementary Sectors
| Sector | Buyer | Target | # of Focused Companies |
|---|---|---|---|
*Healthcare |
|
|
930 |
Biopharmaceuticals |
|
|
374 |
|
Nutritional Health |
|
29 |
- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.
- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.
- Sector Participation. Denotes that the company develops products in this line of business.
Sample Products in Similar Lines of Business |
Sample Products in Complementary Lines of Business |
||
Buyer (Total: 35)
|
Target (Total: 5)
|
Buyer
|
Targetn/a |
Business Relationship Summary:
Top Key Suppliers |
Top Key Customers |
||
Buyer (Total: 5)
|
Target (Total: 6)
|
Buyer (Total: 6)
|
Target (Total: 4)
|
Key Financial Summary:
Key Metrics
| Buyer | Target | |
|---|---|---|
| Number of Employees | 3,443 | 417 |
| Revenue Per Employee | 269,350.8 | 628,751.2 |
| Total Revenue | 231.0 | 65.8 |
| Total Expenses | 217.0 | 75.6 |
Other Revenue
|
0.0 | 0.0 |
|
Cost of Revenue
|
62.1 | 18.2 |
|
SG&A Expense
|
103.6 | 32.1 |
|
Research & Development
|
24.6 | 22.8 |
|
Other Operating Expense
|
0.0 | 0.0 |
|
Operating Income
|
14.0 | -9.7 |
|
Unusual Income
|
6.3 | 0.0 |
|
LT Debt to Capital
|
62.38 | 0 |
|
Fwd P/E
|
23.51 | -33.86 |
|
Fwd P/Rev
|
1.59 | 5.34 |
| Book Value | 468.3 | 392.6 |
|
Curr Portion of LTD/Cap Lease
|
2.2 | 0.0 |
Individual Company Summary
Focused
Buyer
Focused ():
*Healthcare > Biopharmaceuticals
Target
Focused ():
*Healthcare > Biopharmaceuticals > Oncology
Business Description
Buyer
Valeant Pharmaceuticals International is a specialty pharmaceutical company that develops, manufactures and markets a range of pharmaceutical products. The Company focuses on the therapeutic areas of neurology, dermatology and infectious disease. Its products are sold in more than 100 markets through three pharmaceutical segments: North America, International (composed of the Latin America, Asia and Australasia regions), and EMEA (Europe, Middle East and Africa). On October 4, 2006, the Company signed a distribution agreement with Intendis GmbH for rights to certain dermatology products in the United Kingdom. This agreement includes the distribution rights to Finacea, a topical treatment for rosacea. During the year ended December 31, 2006, the Company acquired the rights to Zelapar in Canada and Mexico, and also acquired from Novartis the rights to Melleril in Argentina.
Target
Pharmion Corporation (Pharmion) is a global pharmaceutical company that acquires, develops and commercializes products for the treatment of hematology and oncology patients. It has established a portfolio of approved products and product candidates focused on the hematology and oncology markets. These include Pharmion?s primary commercial products, Vidaza (azacitidine for injection), which it markets and sells as an approved treatment for myelodysplastic syndromes in the United States, Switzerland, Israel and the Philippines. and Thalidomide Pharmion 50 milligram, a therapy for the treatment of multiple myeloma and certain other forms of cancer, which it sells on a compassionate use or named patient basis in certain countries of Europe. Thalidomide Pharmion is approved in Australia, New Zealand, Turkey, Israel, South Korea and Thailand for the treatment of multiple myeloma after the failure of standard therapies. In November 2006, it acquired Cabrellis Pharmaceuticals Corporation.
Deal Summary
Key Ratios
| Buyer | Target | |
|---|---|---|
|
Gross Margin %
|
73.22 | 72.67 |
|
Operating Margin %
|
6.12 | -33.13 |
|
Quick Ratio
|
3.23 | 5.51 |
|
Current Ratio
|
4.03 | 5.98 |
|
Coverage Ratio
|
-0.45 | -0.08 |
| Total Assets | 1,531.0 | 451.4 |
| Return on Equity % | 2.01 | -21.07 |
| Return on Assets % | 0.62 | -18.32 |
|
Cash+ ST Inv. Per Share
|
4.02 | 7.55 |
| Total Debt | 778.7 | 0.0 |
| Total Debt to Equity % | 166.3 | 0 |
| Total Debt to Tangible Equity % | n/a | 0 |
|
Debt to Asset %
|
50.86 | 0.00 |
Product Summary
| Sector | Buyer | Target |
|---|---|---|
|
*Healthcare |
|
|
Biopharmaceuticals |
|
|
|
Cardiovascular System
The Cardiovascular System Subsector includes therapeutics that treat disorders affecting the heart and blood vessels.
|
|
|
|
Dermatology
The Dermatology Subsector includes therapeutics that treat disorders affecting the skin.
|
|
|
|
Digestive System
The Digestive System Subsector includes therapeutics that treat disorders affecting the digestive system.
|
|
|
|
Endocrinology/Metabolism
The Endocrinology/Metabolism Subsector includes therapeutics that treat metabolic disorders and conditions resulting from the dysfunction of hormone secreting glands.
|
|
|
|
Hematology
The Hematology Subsector includes therapeutics that treat blood-based diseases and disorders.
|
|
|
|
Immunology
The Immunology Subsector includes therapeutics that treat disorders affecting the immune system.
|
|
|
|
Infectious Diseases
The Infectious Diseases Subsector includes therapeutics that treat diseases caused by the invasion and reproduction of microorganisms in the body.
|
|
|
|
Neurology
The Neurology Subsector includes therapeutics that treat disorders of the central nervous system, including the brain, spinal cord, and nerves.
|
|
|
|
Oncology
The Oncology Subsector includes therapeutics that treat and manage various types of cancer and related complications.
|
|
|
|
Pain Management
The Pain Management Subsector includes therapeutics that treat and management pain.
|
|
|
|
Surgery
The Surgery Subsector includes therapeutics that treat complications associated with surgical procedures.
|
|
|
|
Toxicology
The Toxicology Subsector includes therapeutics that treat harmful effects from exposure to toxic substances; narcotics, nicotine and alcohol withdrawal therapeutics are also included in this sector.
|
|
|
|
Urology
The Urology Subsector includes therapeutics that treat diseases of the kidney, urinary tract, bladder, and the male reproductive system.
|
|
|
|
Weight Management
The Weight Management Subsectors includes herapeutics that treat and manage weight disorders.
|
|
|
|
Nutritional Health |
|
|
|
Dietary/Naturopathic Supplements
The Dietary/Naturopathic Subsector includes nutritional biochemicals and nutrients derived from natural sources that are intended to support health.
|
|
- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.
- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.
- Sector Participation. Denotes that the company develops products in this line of business.
Product Details
| Sector | Buyer | Target |
|---|---|---|
|
*Healthcare |
|
|
|
Biopharmaceuticals |
|
|
Cardiovascular System |
|
|
Vascular Disorders |
|
|
|
Deep Vein Thrombosis (DVT) |
|
|
|
Anticoagulating Agents (Anticoagulants) |
|
|
|
Thrombin Inhibitors
Therapeutics that prevent or treat clots in blood vessels by preventing blood clots from forming.
Target Products:
|
|
|
|
Thromboembolism |
|
|
|
Anticoagulating Agents (Anticoagulants) |
|
|
|
Thrombin Inhibitors
Therapeutics that treat the obstruction of a blood vessel by preventing blood clots from forming.
Target Products:
|
|
|
|
Dermatology |
|
|
|
Lesion/Scaling Disorders |
|
|
|
Actinic Keratoses |
|
|
|
Antimetabolite Agents |
|
|
|
Pyrimidine Analogs
Therapeutics that treat actinic keratoses by blocking the synthesis of DNA.
Buyer Products:
|
|
|
|
Psoriasis |
|
|
|
Psoralen Derivatives
Plant derived substances that cause increased sensitivity to light and are used to treat a disorder characterized by patches of skin lacking pigment.
Buyer Products:
|
|
|
|
Pigmentation Disorders |
|
|
|
Hyperpigmentation |
|
|
|
Enzymatic Oxidation Inhibitors
Therapeutics that treat disorders characterized by darkening of the skin by inhibiting metabolic processes of pigment producing skin cells.
Buyer Products:
|
|
|
|
Hypopigmentation |
|
|
|
Vitiligo |
|
|
|
Hydroquinone Derivatives
Therapeutics that treat a disorder characterized by patches of skin lacking pigment by permanently removing color from normal skin located around skin with vitiligo.
Buyer Products:
|
|
|
|
Psoralen Derivatives
Plant derived substances that cause increased sensitivity to light and are used to treat a disorder characterized by patches of skin lacking pigment.
Buyer Products:
|
|
|
|
Digestive System |
|
|
|
Gastrointestinal Tract Disorders |
|
|
|
Gastroesophageal Disorders |
|
|
|
Nausea/Vomiting |
|
|
|
Cannabinoids
Therapeutics that treat nausea by producing a sympathomimetic effect on the central nervous system.
Buyer Products:
|
|
|
|
Intestinal Disorders |
|
|
|
Diarrhea |
|
|
|
Antiperistaltic Agents/Anticholinergic Agents
Therapeutics that treat diarrhea by inhibiting the wavelike motion of the digestive tract and blocking the actions of choline and other cholinergic agents.
Buyer Products:
|
|
|
|
Liver Disorders |
|
|
|
Hepatitis |
|
|
|
Hepatitis C |
|
|
|
Chronic |
|
|
|
Interferons
Therapeutics that treat hepatitis by providing a naturally occurring protein that stimulates the immune system.
Buyer Products:
|
|
|
|
Nucleoside Analogs
Therapeutics that treat hepatitis by inhibiting replication of viral DNA by incorporating themselves into growing viral DNA stands.
Buyer Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of digestive disorders in early stages of clinical research where human subject is involved.
Buyer Products:
|
|
|
|
Endocrinology/Metabolism |
|
|
|
Reproductive Disorders |
|
|
|
Abnormal Puberty |
|
|
|
Delayed |
|
|
|
Androgens
Therapeutics that are male sex hormones.
Buyer Products:
|
|
|
|
Hypogonadism |
|
|
|
Male |
|
|
|
Androgens
Therapeutics that are male sex hormones.
Buyer Products:
|
|
|
|
Hematology |
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of hematological disorders in early stages of clinical research where human subject is involved.
Target Products:
|
|
|
|
White Blood Cell (WBC) Disorders |
|
|
|
Myelodysplastic Syndrome |
|
|
|
Antimetabolite Agents |
|
|
|
Pyrimidine Analogs
Therapeutics that treat and manage rmyelodysplastic syndrome by interfering with the production of DNA.
Target Products:
|
|
|
|
Immunology |
|
|
|
Autoimmune Disorders |
|
|
|
Psoriasis |
|
|
|
Psoralen Derivatives
Plant derived substances that cause increased sensitivity to light and are used to treat a disorder characterized by patches of skin lacking pigment.
Buyer Products:
|
|
|
|
Infectious Diseases |
|
|
|
Mycological (Fungal) |
|
|
|
Antifungal Agents |
|
|
|
Broad Spectrum |
|
|
|
Pyrimidine Analogs
Therapeutics that treat fungal infections by interfering with the cell cycle of the fungus.
Buyer Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of infectious diseases in early stages of clinical research where human subject is involved.
Buyer Products:
|
|
|
|
Viral |
|
|
|
RNA Viruses |
|
|
|
Flavivirus |
|
|
|
Hepatitis C |
|
|
|
Chronic |
|
|
|
Interferons
Therapeutics that treat hepatitis by providing a naturally occurring protein that stimulates the immune system.
Buyer Products:
|
|
|
|
Nucleoside Analogs
Therapeutics that treat hepatitis by inhibiting replication of viral DNA by incorporating themselves into growing viral DNA stands.
Buyer Products:
|
|
|
|
Paramyxovirus |
|
|
|
Respiratory Syncytial Virus (RSV) |
|
|
|
Nucleoside Analogs
Therapeutics that treat viral infections in the respiratory tracts of infants by inhibiting replication of viral DNA by incorporating themselves into growing viral DNA stands.
Buyer Products:
|
|
|
|
Neurology |
|
|
|
Neurological Disorders |
|
|
|
Epilepsy |
|
|
|
Partial Seizures |
|
|
|
Complex |
|
|
|
Adjunctive Therapy |
|
|
|
Potassium Channel Modulators/Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat complex partial seizures by preventing the uptake of gamma-aminobutyric acid and opening of potassium channels.
Buyer Products:
|
|
|
|
Monotherapy |
|
|
|
Barbiturates
Therapeutics that treat complex partial seizures by decreasing excitability of neurons.
Buyer Products:
|
|
|
|
Simple |
|
|
|
Adjunctive Therapy |
|
|
|
Potassium Channel Modulators/Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat complex partial seizures by preventing the uptake of gamma-aminobutyric acid and opening of potassium channels.
Buyer Products:
|
|
|
|
Monotherapy |
|
|
|
Barbiturates
Therapeutics that treat simple partial seizures by decreasing excitability of neurons.
Buyer Products:
|
|
|
|
Primary Generalized Seizures |
|
|
|
Tonic-Clonic (Grand Mal) |
|
|
|
Barbiturates
Therapeutics that treat tonic clonic seizures by acting as sedatives through nonselective suppression of central nervous system activities.
Buyer Products:
|
|
|
|
Status Epilepticus |
|
|
|
Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat status epilepticus by enhancing the inhibitory neurotransmitter action of gamma-aminobutyric acid.
Buyer Products:
|
|
|
|
Headaches |
|
|
|
Cluster |
|
|
|
Alpha Adrenergic Blocking Agents
Therapeutics that treat Cluster Headaches by stimulating vascular smooth muscle, causing constriction of both arteries and veins, and depressing vasomotor centers in the brain.
Buyer Products:
|
|
|
|
Tension Type |
|
|
|
Barbiturates/Analgesics/Antipyretics/Stimulants
Therapeutics that treat tension type headaches by decreasing the excitability of neurons and decreasing pain by inhibiting the production of prostaglandins.
Buyer Products:
|
|
|
|
Vascular (Migraine) |
|
|
|
Acute Treatments |
|
|
|
Alpha Adrenergic Blocking Agents
Therapeutics that treat migraines by stimulating vascular smooth muscle, causing constriction of both arteries and veins, and depressing vasomotor centers in the brain.
Buyer Products:
|
|
|
|
Neuromuscular Disorders |
|
|
|
Myasthenia Gravis (MG) |
|
|
|
Cholinesterase Inhibitors
Therapeutics that treat Myasthenia Gravis by maintaining the transmission of nerve impulses by inhibiting the enzyme that breaks down acetylcholine.
Buyer Products:
|
|
|
|
Parkinson`s Disease (PD) |
|
|
|
Adjunctive Treatments |
|
|
|
Catechol-O-Methyl Transferase (COMT) Inhibitors
Therapeutics that treat the disorder involving nerve cell loss in portions of the brain that leads to uncontrolled tremors, abnormal posture and speech problems by inhibiting the action of catachol-o-methyl transferase.
Buyer Products:
|
|
|
|
Dopamine Receptor Agonists
Therapeutics that assist in the treatment of the disorder involving nerve cell loss in portions of the brain that leads to uncontrolled tremors, abnormal posture and speech problems by stimulating dopamine receptors on neurons.
Buyer Products:
|
|
|
|
Monoamine Oxidase (MAO) Inhibitors
Therapeutics that assist in the treatment of the disorder involving nerve cell loss in portions of the brain that leads to uncontrolled tremors, abnormal posture and speech problems by inhibiting the degradation of neurotransmitters.
Buyer Products:
|
|
|
|
Monotherapy |
|
|
|
Dopamine Receptor Agonists
Therapeutics that treat the disorder involving nerve cell loss in portions of the brain that leads to uncontrolled tremors, abnormal posture and speech problems by stimulating dopamine receptors on the neurons.
Buyer Products:
|
|
|
|
Psychiatric Disorders |
|
|
|
Anxiety |
|
|
|
Generalized Anxiety Disorder (GAD) |
|
|
|
Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat anxiety by enhancing the inhibitory neurotransmitter action of gamma-aminobutyric acid.
Buyer Products:
|
|
|
|
Gamma-Aminobutyric Acid (GABA) Receptor Agonists/Tricyclic Antidepressants
Therapeutics that treat anxiety by enhancing the inhibitory neurotransmitter action of gamma-aminobutyric acid as well as increasing the synaptic concentrations of norepinephrine and serotonin.
Buyer Products:
|
|
|
|
Mood Disorders |
|
|
|
Depression |
|
|
|
Gamma-Aminobutyric Acid (GABA) Receptor Agonists/Tricyclic Antidepressants
Therapeutics that treat anxiety by enhancing the inhibitory neurotransmitter action of gamma-aminobutyric acid as well as increasing the synaptic concentrations of norepinephrine and serotonin.
Buyer Products:
|
|
|
|
Sleep Disorders |
|
|
|
Insomnia |
|
|
|
Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat insomnia by enhancing the inhibitory action of gamma-aminobutyric acid.
Buyer Products:
|
|
|
|
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of nervous system and mental disorders in very early stages of research where no human subject is involved.
Buyer Products:
|
|
|
|
Oncology |
|
|
|
Breast Cancer |
|
|
|
Palliative Agents |
|
|
|
Hormonal Treatments |
|
|
|
Androgens
Therapeutics that treat and manage breast cancer by providing male hormones.
Buyer Products:
|
|
|
|
Dermatology |
|
|
|
Basal Cell Carcinoma |
|
|
|
Antimetabolite Agents |
|
|
|
Pyrimidine Analogs
Therapeutics that treat and manage cancers arising from the epidermal basal cells by inhibiting the production of DNA.
Buyer Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment and management of cancer in early stages of clinical research where human subject is involved.
Target Products:
|
|
|
|
Pain Management |
|
|
|
Anesthesia |
|
|
|
General (Systemic) |
|
|
|
Adjunctive |
|
|
|
Opioids
Therapeutics that treat pain by binding to certain nervous system receptors which alters both the perception of pain as well as the emotional response to pain.
Buyer Products:
|
|
|
|
Narcotics |
|
|
|
Opioids
Therapeutics that treat pain by binding to certain nervous system receptors which alter both the perception of pain as well as the emotional response to pain.
Buyer Products:
|
|
|
|
Surgery |
|
|
|
General |
|
|
|
Restlessness/Apprehension |
|
|
|
Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat the nervousness which precedes surgery by increasing the action of gamma aminobutyric acid at the relevant neuroreceptors.
Buyer Products:
|
|
|
|
Musculoskeletal System |
|
|
|
Deep Vein Thrombosis (DVT) |
|
|
|
Anticoagulating Agents (Anticoagulants) |
|
|
|
Thrombin Inhibitors
Therapeutics that treat vascular obstructions due to platelets and cell matter by blocking an enzyme involved in the clotting process.
Target Products:
|
|
|
|
Toxicology |
|
|
|
Substance Abuse |
|
|
|
Withdrawal |
|
|
|
Alcohol |
|
|
|
Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat alcohol withdrawal by increasing the effect of GABA at the relevant neuroreceptors.
Buyer Products:
|
|
|
|
Urology |
|
|
|
Male Genital Disorders |
|
|
|
Testicular |
|
|
|
Abnormal Puberty |
|
|
|
Delayed |
|
|
|
Androgens
Therapeutics that treat puberty disorders by providing male sex hormones.
Buyer Products:
|
|
|
|
Hypogonadism |
|
|
|
Androgens
Therapeutics that treat hypogonadism by providing male sex hormones.
Buyer Products:
|
|
|
|
Weight Management |
|
|
|
Obesity |
|
|
|
Sympathomimetic Agents
Therapeutics that suppress appetite by stimulating the adrenergic receptors and produce adrenergic chemicals.
Buyer Products:
|
|
|
|
Nutritional Health |
|
|
|
Dietary/Naturopathic Supplements |
|
|
|
General Health
Products consisting of dietary/naturopathic supplements that are intended to support general health.
Buyer Products:
|
|
- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.
- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.
- Sector Participation. Denotes that the company develops products in this line of business.
Relationship Details
Key Competitors
| Name | Dir | Percent | Market Cap. | P/E Ratio (TTM) | Fwd P/E | P/R Ratio (TTM) | Fwd P/Rev | Price To Tang. Book Value | |
|---|---|---|---|---|---|---|---|---|---|
| Buyer | |||||||||
Roche Holding Ltd. (ADR)
|
|
n/a | 151,465.984 | 20.72 | 18.68 | 4.06 | 3.85 | 6.08 | |
|
Novartis AG (ADR)
|
|
n/a | 123,142.627 | 20.22 | 15.93 | 3.24 | 3.28 | 5.45 | |
|
Wyeth
|
|
n/a | 63,157.789 | 14.15 | 13.20 | 2.96 | 2.82 | 5.40 | |
|
Schering-Plough Corporation
|
|
n/a | 46,100.910 | 30.15 | 21.79 | 4.05 | 3.78 | 5.49 | |
|
Gilead Sciences, Inc.
|
|
n/a | 34,543.911 | n/a | 22.53 | 9.27 | 8.20 | 14.64 | |
|
Allergan, Inc.
|
|
n/a | 18,386.844 | 43.28 | 27.53 | 5.24 | 4.87 | 61.15 | |
|
Shire plc (ADR)
|
|
n/a | 14,226.512 | n/a | 36.00 | 6.94 | 6.15 | n/a | |
|
Forest Laboratories, Inc.
|
|
n/a | 11,985.247 | 22.97 | 12.05 | 3.37 | 3.22 | 3.90 | |
|
Cephalon, Inc.
|
|
n/a | 4,933.150 | 30.51 | 18.31 | 2.66 | 2.72 | 18.73 | |
|
Vertex Pharmaceuticals Incorporated
|
|
n/a | 4,920.056 | n/a | -12.95 | 19.33 | 16.98 | 11.87 | |
|
King Pharmaceuticals, Inc.
|
|
n/a | 3,822.833 | 12.41 | 8.40 | 1.85 | 1.79 | 2.82 | |
|
Mylan Laboratories Inc.
|
|
n/a | 3,789.250 | 17.11 | 9.39 | 2.10 | 1.81 | 4.92 | |
|
Watson Pharmaceuticals, Inc.
|
|
n/a | 3,198.536 | n/a | 24.02 | 1.37 | 1.27 | 16.16 | |
|
Biovail Corporation (USA)
|
|
n/a | 2,792.151 | 12.72 | 9.52 | 2.68 | 3.26 | 4.59 | |
| Target | |||||||||
|
Pfizer Inc.
|
|
n/a | 171,376.673 | 9.81 | 11.67 | 3.54 | 3.59 | 7.08 | |
|
GlaxoSmithKline plc (ADR)
|
|
n/a | 147,633.521 | 13.74 | 12.93 | 3.26 | 3.18 | 11.93 | |
|
sanofi-aventis (ADR)
|
|
n/a | 110,358.897 | 20.89 | 11.15 | 2.73 | 2.80 | n/a | |
|
Genentech, Inc.
|
|
n/a | 77,408.387 | 29.60 | 27.16 | 7.07 | 6.56 | 8.50 | |
|
Eli Lilly & Co.
|
|
n/a | 64,211.763 | 29.48 | 16.15 | 3.78 | 3.51 | 7.08 | |
|
Celgene Corporation
|
|
n/a | 22,887.252 | 147.05 | 63.43 | 19.71 | 16.31 | 10.65 | |
|
Millennium Pharmaceuticals, Inc.
|
|
n/a | 3,159.846 | n/a | n/a | 6.75 | 6.79 | 5.10 | |
|
MGi Pharma, Inc.
|
|
n/a | 1,973.519 | n/a | 65.08 | 5.58 | 4.83 | 576.21 | |
|
SuperGen, Inc.
|
|
n/a | 250.030 | n/a | 52.63 | 12.35 | n/a | 2.87 | |
|
Poniard Pharmaceuticals, Inc.
|
|
n/a | 213.831 | n/a | -4.59 | n/a | 19.16 | 2.32 | |
|
Vion Pharmaceuticals, Inc.
|
|
n/a | 60.465 | n/a | -1.45 | 3,040.29 | 526.50 | 2.81 | |
- Defined by the Company
- Defined by Others
Dependent Suppliers
| Name | Dir | Percent | Market Cap. | P/E Ratio (TTM) | Fwd P/E | P/R Ratio (TTM) | Fwd P/Rev | Price To Tang. Book Value | |
|---|---|---|---|---|---|---|---|---|---|
| Buyer | |||||||||
|
Roche Holding Ltd. (ADR)
|
|
n/a | 151,465.984 | 20.72 | 18.68 | 4.06 | 3.85 | 6.08 | |
|
PAREXEL International Corporation
|
|
n/a | 1,234.468 | 33.11 | 26.94 | 1.34 | 1.39 | n/a | |
|
POZEN Inc.
|
|
n/a | 289.251 | n/a | -13.51 | 9.65 | 8.09 | 12.73 | |
|
Senetek PLC (ADR)
|
|
n/a | 20.727 | 0.88 | n/a | 0.66 | n/a | 1.00 | |
|
Jazz Pharmaceuticals, Inc.
|
|
n/a | n/a | n/a | -2.00 | n/a | n/a | n/a | |
| Target | |||||||||
|
GPC Biotech AG (ADR)
|
|
66.00% | 410.384 | n/a | n/a | 16.12 | n/a | 4.52 | |
|
Celgene Corporation
|
|
n/a | 22,887.252 | 147.05 | 63.43 | 19.71 | 16.31 | 10.65 | |
|
salesforce.com, inc.
|
|
n/a | 4,839.024 | 910.55 | 394.30 | 7.89 | 6.27 | 15.10 | |
|
MethylGene Inc.
|
|
n/a | 141.227 | n/a | n/a | 7.77 | n/a | 2.72 | |
|
Ben Venue Laboratories, Inc.
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
|
Ash Stevens, Inc.
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
- Defined by the Company
- Defined by Others
Key Customers
| Name | Dir | Percent | Market Cap. | P/E Ratio (TTM) | Fwd P/E | P/R Ratio (TTM) | Fwd P/Rev | Price To Tang. Book Value | |
|---|---|---|---|---|---|---|---|---|---|
| Overlap | |||||||||
|
McKesson Corporation
|
|
17.30% | 17,521.748 | 18.18 | 18.00 | 0.19 | 0.17 | 5.38 | |
| Buyer | |||||||||
|
McKesson Corporation
|
|
17.30% | 17,521.748 | 18.18 | 18.00 | 0.19 | 0.17 | 5.38 | |
|
Roche Holding Ltd. (ADR)
|
|
n/a | 151,465.984 | 20.72 | 18.68 | 4.06 | 3.85 | 6.08 | |
|
Schering-Plough Corporation
|
|
n/a | 46,100.910 | 30.15 | 21.79 | 4.05 | 3.78 | 5.49 | |
|
Metabasis Therapeutics, Inc.
|
|
n/a | 88.556 | n/a | -2.17 | 11.80 | 10.78 | 1.74 | |
|
Ardea Biosciences, Inc.
|
|
n/a | 71.752 | n/a | n/a | 80.33 | n/a | 1.56 | |
|
Anadys Pharmaceuticals, Inc.
|
|
n/a | 69.049 | n/a | -2.31 | 14.69 | 12.29 | 1.41 | |
| Target | |||||||||
|
US Oncology, Inc.
|
|
19.00% | n/a | n/a | n/a | n/a | n/a | n/a | |
|
Cardinal Health, Inc.
|
|
11.00% | 26,829.234 | 13.89 | 16.91 | 0.31 | 0.28 | 17.70 | |
|
McKesson Corporation
|
|
9.00% | 17,521.748 | 18.18 | 18.00 | 0.19 | 0.17 | 5.38 | |
|
Government - United Kingdom
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
- Defined by the Company
- Defined by Others
Key Partners
| Name | Dir | Percent | Market Cap. | P/E Ratio (TTM) | Fwd P/E | P/R Ratio (TTM) | Fwd P/Rev | Price To Tang. Book Value | |
|---|---|---|---|---|---|---|---|---|---|
| Buyer | |||||||||
|
Roche Holding Ltd. (ADR)
|
|
n/a | 151,465.984 | 20.72 | 18.68 | 4.06 | 3.85 | 6.08 | |
|
Schering-Plough Corporation
|
|
n/a | 46,100.910 | 30.15 | 21.79 | 4.05 | 3.78 | 5.49 | |
|
Allergan, Inc.
|
|
n/a | 18,386.844 | 43.28 | 27.53 | 5.24 | 4.87 | 61.15 | |
|
PAREXEL International Corporation
|
|
n/a | 1,234.468 | 33.11 | 26.94 | 1.34 | 1.39 | n/a | |
|
POZEN Inc.
|
|
n/a | 289.251 | n/a | -13.51 | 9.65 | 8.09 | 12.73 | |
|
Metabasis Therapeutics, Inc.
|
|
n/a | 88.556 | n/a | -2.17 | 11.80 | 10.78 | 1.74 | |
|
Ardea Biosciences, Inc.
|
|
n/a | 71.752 | n/a | n/a | 80.33 | n/a | 1.56 | |
|
Anadys Pharmaceuticals, Inc.
|
|
n/a | 69.049 | n/a | -2.31 | 14.69 | 12.29 | 1.41 | |
|
Senetek PLC (ADR)
|
|
n/a | 20.727 | 0.88 | n/a | 0.66 | n/a | 1.00 | |
|
Jazz Pharmaceuticals, Inc.
|
|
n/a | n/a | n/a | -2.00 | n/a | n/a | n/a | |
| Target | |||||||||
|
Pfizer Inc.
|
|
n/a | 171,376.673 | 9.81 | 11.67 | 3.54 | 3.59 | 7.08 | |
|
Cardinal Health, Inc.
|
|
n/a | 26,829.234 | 13.89 | 16.91 | 0.31 | 0.28 | 17.70 | |
|
Celgene Corporation
|
|
n/a | 22,887.252 | 147.05 | 63.43 | 19.71 | 16.31 | 10.65 | |
|
McKesson Corporation
|
|
n/a | 17,521.748 | 18.18 | 18.00 | 0.19 | 0.17 | 5.38 | |
|
MGi Pharma, Inc.
|
|
n/a | 1,973.519 | n/a | 65.08 | 5.58 | 4.83 | 576.21 | |
|
GPC Biotech AG (ADR)
|
|
n/a | 410.384 | n/a | n/a | 16.12 | n/a | 4.52 | |
|
MethylGene Inc.
|
|
n/a | 141.227 | n/a | n/a | 7.77 | n/a | 2.72 | |
|
Dainippon Sumitomo Pharma Co., Ltd.
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
|
US Oncology, Inc.
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
|
LEO Pharma A/S
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
|
Nippon Shinyaku Co., Ltd.
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
|
Ben Venue Laboratories, Inc.
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
|
Ash Stevens, Inc.
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
- Defined by the Company
- Defined by Others
Financials
| Buyer | Target | Combined Entity | |
|---|---|---|---|
| Income Statement | |||
| Operating Items | |||
| Revenue | 921.7 | 250.2 | 1,171.9 |
|
Other Revenue
|
0.0 | 0.0 | 0.0 |
| Total Revenue | 921.7 | 250.2 | 1,171.9 |
|
Cost of Revenue
|
246.8 | 68.4 | 315.2 |
|
SG&A Expense
|
386.6 | 117.1 | 503.7 |
|
Depreciation & Amortization
|
76.3 | 9.8 | 86.1 |
|
Research & Development
|
100.9 | 79.5 | 180.4 |
|
Interest Expense
|
0.0 | 0.0 | 0.0 |
|
Other Operating Expense
|
0.0 | 0.0 | 0.0 |
|
Unusual Expense (Income)
|
54.7 | 58.3 | 112.9 |
| Total Expenses | 865.3 | 333.1 | 1,198.4 |
|
Operating Income
|
56.4 | -82.9 | -26.5 |
| Non Operating Items | |||
|
Interest Expense (Inc.), Net Non-Oprtng
|
-25.5 | 7.0 | -18.5 |
|
Other, Net
|
0.0 | 0.0 | 0.0 |
| Income Before Taxes | 30.9 | -75.9 | -45.0 |
| Income Taxes | 21.5 | 6.8 | 28.3 |
| Income After Taxes | 9.4 | -82.7 | -73.3 |
| Minority Interest (IS) | -0.0 | 0.0 | -0.0 |
|
Net Income - Excl. Xord. Items
|
9.4 | -82.7 | -73.3 |
| Discontinued Operations | 7.5 | 0.0 | 7.5 |
|
Net Income - Incl. Xord. Items
|
16.9 | -82.7 | -65.8 |
|
Income Avail. to Common
|
16.9 | -82.7 | -65.8 |
| Share Items | |||
|
Basic Avg. Shares Outstanding
|
94.9 | 34.3 | 129.2 |
|
Basic EPS - Excl. Xord. Items
|
0.10 | n/a | -0.57 |
|
Basic EPS - Incl. Xord. Items
|
0.18 | n/a | -0.51 |
| Full Dilution Adjustment | 0.0 | 0.0 | 0.0 |
| Fully Diluted Shares Outstanding | 96.2 | 34.3 | 130.5 |
|
F.D. EPS - Excl. Xord. Items
|
0.10 | n/a | -0.56 |
|
F.D. EPS - Incl. Xord. Items
|
0.18 | n/a | -0.50 |
| Dividends Per Common Share | 0.08 | 0.00 | 0.08 |
| Balance Sheet | |||
| Assets | |||
|
Cash and Equivalents
|
377.4 | 159.0 | 536.4 |
|
ST Investments
|
9.2 | 100.3 | 109.5 |
|
Accounts Receivable
|
217.9 | 44.6 | 262.6 |
|
Inventory
|
126.2 | 12.3 | 138.5 |
|
Prepayments and Advances
|
16.9 | 0.0 | 16.9 |
|
Other Current Assets
|
6.3 | 13.3 | 19.5 |
|
Current Assets
|
754.0 | 329.4 | 1,083.4 |
|
PPE
|
198.3 | 0.0 | 198.3 |
|
Accum D&A
|
-96.4 | 0.0 | -96.4 |
|
PPE, Net
|
102.0 | 9.4 | 111.4 |
| Goodwill & Intangibles | 559.6 | 105.6 | 665.3 |
| Other Assets | 0.0 | 0.0 | 0.0 |
|
Other LT Assets
|
115.4 | 7.0 | 122.4 |
| Total Assets | 1,531.0 | 451.4 | 1,982.4 |
| Liabilities | |||
| Accounts Payable | 52.5 | 9.2 | 61.7 |
| Payable/Accrued | 0.0 | 0.0 | 0.0 |
| Accrued Expenses | 127.2 | 45.9 | 173.1 |
|
ST Debt
|
0.0 | 0.0 | 0.0 |
|
Curr Port of LTD & Cap Lease Oblg
|
2.2 | 0.0 | 2.2 |
| Other (Current) Liabilities | 5.3 | 0.0 | 5.3 |
|
Current Liab.
|
187.3 | 55.1 | 242.4 |
|
LT Debt
|
776.5 | 0.0 | 776.5 |
|
Total LT Debt
|
776.5 | 0.0 | 776.5 |
| Deferred Taxes | 1.4 | 2.8 | 4.2 |
|
Other LT Liab.
|
97.5 | 0.9 | 98.5 |
|
Total Liabilities
|
1,062.7 | 58.8 | 1,121.6 |
| Shareholders Equity | |||
| Common Stock | 0.9 | 0.0 | 1.0 |
| Additional Paid in Capital | 1,253.6 | 622.1 | 1,875.6 |
| Retained Earnings | -825.0 | -241.8 | -1,066.8 |
| Other Equity | 38.8 | 12.2 | 51.0 |
|
Total Equity
|
468.3 | 392.6 | 860.9 |
|
Total Liab. & Equity
|
1,531.0 | 451.4 | 1,982.4 |
|
Shares Outstanding
|
93.7 | 36.8 | 130.5 |
| Cash Flow | |||
| Operating Cash Flow | |||
| CF Net Income | 16.9 | -82.7 | -65.8 |
| CF Depreciation | 92.6 | 12.2 | 104.9 |
| CF Deferred Taxes | 19.2 | 0.0 | 19.2 |
| Other Non-Cash Items | 75.2 | 3.3 | 78.5 |
| Change in Working Capital | -73.5 | 7.9 | -65.6 |
| Total Cash From Operating Activities | 130.5 | -59.2 | 71.2 |
| Investing Cash Flow (not calculated) | |||
| Capital Expenditures | -37.9 | -5.1 | -43.0 |
| Other Investing Cash Flows | 35.1 | -3.9 | 31.2 |
| Total Cash From Investing Activities | -2.8 | -9.0 | -11.8 |
| Financing Cash Flow (not calculated) | |||
| Dividends Paid | -7.2 | 0.0 | -7.2 |
| Purchase Or Sale of Stock | -2.3 | 2.2 | -0.1 |
| Purchase and Retirement of Debt | -4.7 | -1.0 | -5.7 |
| Other Financing Cash Flow | 0.0 | 130.8 | 130.8 |
| Total Cash From Financing Activities | -14.2 | 132.0 | 117.8 |
| Exchange Rate Effects | 19.3 | 2.0 | 21.3 |
| Net Change in Cash | 132.8 | 65.7 | 198.5 |
| Cash Taxes Paid | 42.1 | 11.4 | 53.4 |
| Cash Interest Paid | 38.1 | 0.4 | 38.5 |